Dxcover
The mission of Dxcover® is to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life. A University of Strathclyde spin-out, its first product will rapidly fast-track patients with suspected brain tumours for further treatment saving months of GP visits and specialist scans.
Dxcover® has conducted clinical trials with its ‘drop, dry, detect’ technology. To advance commercial plans, the team wanted to create a single platform capable of handling data from laboratories across the world.
Dxcover® is using deckchair® to accelerate the delivery of its cancer diagnostic system for clinical blood samples. The efficiency savings that deckchair® provides will enable quicker and more economic clinical trials as Dxcover® builds towards a globally available, cloud hosted product.
